Beximco Pharmaceuticals PLC. announcements
297 Dhaka Stock Exchange announcements for Beximco Pharmaceuticals PLC. (BXPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2023 (23).
- Credit Rating Information and Services Limited (CRISL) has assigned rating of the Company as \"AAA\" in the long term an
Credit Rating Information and Services Limited (CRISL) has assigned rating of the Company as \"AAA\" in the long term and \"ST-1\" for short term along with Stable outlook in consideration of its audited financials up to June 30, 2023 also unaudited financials up to September 30, 2023 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Resumption after Record date
Trading of the shares of the company will resume on 14.11.2023.
- Suspension for Record date
Trading of the shares of the company will remain suspended on record date i.e., 13.11.2023.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 09.11.2023 to 12.11.2023 and trading of the shares will remain suspended on record date i.e., 13.11.2023.
- (Q1 Un-audited): Consolidated EPS was Tk. 3.48 for July-September 2023 as against Tk. 3.24 for July-September 2022; Cons
(Q1 Un-audited): Consolidated EPS was Tk. 3.48 for July-September 2023 as against Tk. 3.24 for July-September 2022; Consolidated NOCFPS was Tk. 6.07 for July-September 2023 as against Tk. 1.53 for July-September 2022. NAV per share was Tk. 101.40 as on September 30, 2023 and Tk. 94.25 as on September 30, 2022. (cont.)
- Q1 Financials
(Continuation news of BXPHARMA): Reasons for deviation in NOCFPS: In the first quarter of comparable prior year, cash out flows for inventories were notably higher because of strategic buildup of inventories to protect against any supply chain disruption. This, together with improved working capital and revenue growth, resulted in a positive deviation in current period's Operating Cash Flows per share. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 05, 2023 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
- The Board of Directors has recommended 35\% cash dividend for the year ended June 30, 2023. Date of AGM: 28.12.2023, Tim
The Board of Directors has recommended 35\% cash dividend for the year ended June 30, 2023. Date of AGM: 28.12.2023, Time: 10:30 AM, Venue: Digital Platform. Record Date: 13.11.2023. The Company has also reported Consolidated EPS of Tk. 10.34, Consolidated NAV per share of Tk. 97.91 and Consolidated NOCFPS of Tk. 13.64 for the year ended June 30, 2023 (cont.1)
- (Continuation news of BXPHARMA): as against Consolidated EPS of Tk. 11.48, Consolidated NAV per share of Tk. 91.01 and C
(Continuation news of BXPHARMA): as against Consolidated EPS of Tk. 11.48, Consolidated NAV per share of Tk. 91.01 and Consolidated NOCFPS of Tk. 11.69 respectively for the year ended June 30, 2022. Reasons for deviation in EPS: EPS has been decreased primarily because, during the period July 2021 to June 2022, the company earned a non-recurring pre-tax income of Taka 619 million as Vaccine Distribution Fee under a contractual agreement. (cont.2)
The first part of this announcement is missing from the archive. - Dividend Declaration
(Continuation news of BXPHARMA): As this particular contract has concluded, there has been no income from this source in the current reporting period. Additionally, rising costs, driven by sharp depreciation of BDT against USD and high inflation have further impacted the EPS. (end)
The first part of this announcement is missing from the archive. - Price Limit Open
There will be no price limit on the trading of the shares of the Company on today (22.10.2023) for following its corporate declaration. However, the floor price shall be applicable accordingly.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 19, 2023 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
- Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 2.13 for January-March 2023 as against Tk. 2.47 for January-March 2022; Consolidated EPS was Tk. 8.15 for July 2022-March 2023 as against Tk. 9.60 for July 2021-March 2022. Consolidated NOCFPS was Tk. 9.66 for July 2022-March 2023 as against Tk. 8.88 for July 2021-March 2022. Consolidated NAV per share was Tk. 95.65 as on March 31, 2023 and Tk. 89.13 as on March 31, 2022. EPS has been decreased due to increased cost of production and a decrease in gross margin.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2023 at 11:30 AM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
- Sale and Buy confirmations of Directors
IFIC Securities Limited, one of the Corporate Directors of the Company, has further informed that it has completed its sale of 40,00,000 shares whereas New Dacca Industries Limited, another Corporate Director of the company, has also informed that it has completed its buying of 40,00,000 shares through Dhaka Stock Exchange Limited as per declaration disseminated on 04.04.2023.
- Sale and Buy Declarations of Directors
IFIC Securities Limited, one of the Corporate Directors of the Company, has expressed its intention to sell 40,00,000 shares (in the Block Market) whereas New Dacca Industries Limited, another Corporate Director of the company, has expressed its intention to buy 40,00,000 shares (in the Block Market) at prevailing market price through Dhaka Stock Exchange Limited within next 30 working days.
- Sale and Buy confirmations of Directors
IFIC Securities Limited, one of the Corporate Directors of the Company, has further informed that it has completed its sale of 1,70,00,000 shares whereas Absolute Construction & Engineering Ltd., another Corporate Director of the company, has also informed that it has completed its buying of 1,70,00,000 shares through Dhaka Stock Exchange Limited as per declaration disseminated on 13.03.2023.
- Sale and Buy Declarations of Directors
IFIC Securities Limited, one of the Corporate Directors of the Company, has expressed its intention to sell 1,70,00,000 shares (in the Block Market) whereas Absolute Construction & Engineering Ltd., another Corporate Director of the company, has expressed its intention to buy 1,70,00,000 shares (in the Block Market) at prevailing market price through Dhaka Stock Exchange within next 30 working days.
- (Q2 Un-audited): Consolidated EPS was Tk. 2.77 for October-December 2022 as against Tk. 3.84 for October-December 2021;
(Q2 Un-audited): Consolidated EPS was Tk. 2.77 for October-December 2022 as against Tk. 3.84 for October-December 2021; Consolidated EPS was Tk. 6.02 for July-December 2022 as against Tk. 7.12 for July-December 2021. Consolidated NOCFPS was Tk. 5.33 for July-December 2022 as against Tk. 8.22 for July-December 2021. Consolidated NAV per share was Tk. 93.52 as on December 31, 2022 and Tk. 86.65 as on December 31, 2021. (Cont.1)
- (Continuation news of BXPHARMA): Reasons for deviation in EPS and NOCFPS: EPS has declined due to increased cost of prod
(Continuation news of BXPHARMA): Reasons for deviation in EPS and NOCFPS: EPS has declined due to increased cost of production and a consequent decrease in gross margin. Moreover, during July-December 2021 period, the Company earned a net amount of BDT 619.00 million as Vaccine Distribution Fee from the distribution of Oxford/AstraZeneca COVID-19 vaccine under a tripartite agreement between the Serum Institute of India (SII), Government of Bangladesh (GOB) and BEXIMCO Pharma. (cont.2)
The first part of this announcement is missing from the archive. - Q2 Financials
(Continuation news of BXPHARMA): With the end of the contract, there has been no income from this source in the reporting period. NOCFPS has declined due to increased working capital investment consequent to the record devaluation of Taka, increased price of materials and higher domestic inflation. Moreover, the Company needed to maintain additional inventory to protect against any supply chain disruption and to support the organic business growth. (end)
The first part of this announcement is missing from the archive. - Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended June 30, 2022 to the respective shareholders.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2023 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.